Startseite
Kongressberichte & Archiv
Archiv 2019
ESMO World Congress on Gastrointestinal Cancer
Presentation of Selected Rectal Cancer Abstracts
Presentation of Selected Rectal Cancer Abstracts
O-010: VOLTAGE: Investigator-Initiated Clinical Trial of Nivolumab Monotherapy and Subsequent Radical Surgery Following Preoperative Chemoradiotherapy in Patients with Microsatellite Stable Locally Advanced Rectal Cancer
Takayuki Yoshino, et al.
Takayuki Yoshino, et al.
The conclusion from authors abstract:
A promising pCR rate of 30%, with mild toxicity, was shown in MSS LARC pts treated with nivo plus radical surgery. PD-L1 expression and elevated CD8/T reg ratio may be better predictors of nivo benefit, warranting further study in a larger cohort.
O-011: Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12
Ralf-Dieter Hofheinz, et al.
O-011: Randomized phase II trial of chemoradiotherapy plus induction or consolidation chemotherapy as total neoadjuvant therapy for locally advanced rectal cancer: CAO/ARO/AIO-12
Ralf-Dieter Hofheinz, et al.
The conclusion from authors abstract:
Upfront CRT followed by consolidation CT was feasible, resulted in better compliance to CRT but worse compliance to CT compared to group A. Long term follow-up is required to assess if improved pCR in arm B translate to better oncological outcome.